Retrotope

Retrotope announced that enrollment had opened for the highest-dose cohort of its RT001 clinical trial for Friedreich’s ataxia after a safety review.

Retrotope and collaborators planned to present a poster at the 2017 American Academy of Neurosciences Meeting in Boston on a stabilized PUFA drug’s efficacy in multiple Alzheimer’s models.

Retrotope’s first-in-human clinical trial achieved its safety, tolerability, and pharmacokinetic goals, with early signals of efficacy. Dr. Theresa Zesiewicz was the principal investigator.

The company collaborates with employees and industry partners, draws talent from Silicon Valley and around the world, and has a scientific advisory board.

The Clinical Research Associate provides coordination and management support for Retrotope-sponsored clinical trials.

The Director of Program Management reports to the Chief Business Officer and is responsible for driving and integrating the company’s pre-launch program.

Retrotope is developing drugs designed to combat disease and cellular degeneration resulting from lipid peroxidation (LPO).

Retrotope is a clinical-stage biopharmaceutical company developing therapies for degenerative diseases, from orphan neurodegenerative indications to large-market degenerative conditions.

Retrotope is developing a pipeline of proprietary therapeutics designed to treat degenerative disease by down-regulating LPO in order to protect against cellular degeneration.